trending Market Intelligence /marketintelligence/en/news-insights/trending/cootukzlextx-dxmrub_5a2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

Blog

JMP Securities is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition


Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

Sage Therapeutics Inc. and Shionogi & Co. Ltd. entered a collaboration to develop and sell its experimental drug Sage-217 for treating major depressive disorder and other indications.

Under the deal, Osaka, Japan-based Shionogi will shoulder clinical development, regulatory filings and commercialization of Sage-217 in Japan, Taiwan and South Korea.

Shionogi will pay Cambridge, Mass.-based Sage $90 million up front. The latter will also be eligible to receive up to $485 million in milestone payments as well as tiered royalties on sales of Sage-217.

Further, Shionogi granted Sage certain rights to co-promote Sage-217 in Japan in all indications, while Sage maintains the exclusive rights to develop and sell Sage-217 outside of Japan, Taiwan and South Korea.

In February, Sage-217 was granted breakthrough therapy designation by the U.S. Food and Drug Administration based on data from a phase 2 study.